Page 371 - Read Online

Page 8 of 9 Salleh et al. J Cancer Metastasis Treat 2020;6:31 I http://dx.doi.org/10.20517/2394-4722.2020.70

single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol 2015;4:29.
8. Lee HS, Jang CY, Kim SA, Park SB, Jung DE, et al. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic
cancer. Scientific reports. 2018;8:1-7.
9. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 response: a surrogate to predict survival in patients with metastatic pancreatic
adenocarcinoma. Am J Clin Oncol 2019;42:898-902.
10. Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, et al. Identification of blood-protein carriers of the CA 19-9 antigen and
characterization of prevalence in pancreatic diseases. Proteomics 2011;11:3665-74.
11. Herrero-Zabaleta ME, Gautier R, Burtin P, Daher N, Bara J. Monoclonal antibody against sialylated Lewis (a) antigen. Bull Cancer
1987;74:387-96.
12. Jelski W, Chrostek L, Szmitkowski M. The activity of class I, II, III, and IV of alcohol dehydrogenase isoenzymes and aldehyde
dehydrogenase in pancreatic cancer. Pancreas 2007;35:142-6.
13. Jelski W, Zalewski B, Szmitkowski M. Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the
sera of patients with pancreatic cancer. Dig Dis Sci 2008;53:2276-80.
14. Jelski W, Kutylowska E, Laniewska-Dunaj M, Szmitkowski M. Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) as
candidates for tumor markers in patients with pancreatic cancer. J Gastrointestin Liver Dis 2011;20:255-9.
15. Moniaux N, Andrianifahanana M, Brand RE, Batra SK. Multiple roles of mucins in pancreatic cancer, a lethal and challenging
malignancy. Br J Cancer 2004;91:1633-8.
16. Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol
2013;10:607.
17. Munkley J. The glycosylation landscape of pancreatic cancer. Oncol Lett 2019;17:2569-75.
18. Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, et al. Carbohydrate antigen 19-9 elevation in anatomically resectable,
early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a
national cancer database study. J Am Coll Surg 2016;223:52-65.
19. Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome
in pancreatic adenocarcinoma. Ann Surg Oncol 2014;21:4351-8.
20. Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, et al. Low-dose continuous 5-fluorouracil combined with leucovorin, nab-paclitaxel,
oxaliplatin, and bevacizumab for patients with advanced pancreatic cancer: a retrospective analysis. Target Oncol 2018;13:461-8.
21. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic
and prognostic updates. Curr Mol Med 2013;13:340-51.
22. Wu Z, Kuntz AI, Wadleigh RG. CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer. Clin Adv Hematol
Oncol 2013;11:50-5.
23. Distler M, Pilarsky E, Kersting S, Grützmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative
resection for ductal adenocarcinoma of the pancreas-a retrospective tumor marker prognostic study. Int J Surg 2013;11:1067-72.
24. Paschos KA, Canovas D, Bird NC. The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med
2010;14:165-74.
25. Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, et al. Trefoil factor(s) and CA19. 9: a promising panel for early detection of
pancreatic cancer. E BioMedicine 2019;42:375-85.
26. Houghton JL, Abdel-Atti D, Scholz WW, Lewis JS. Preloading with unlabeled CA19. 9 targeted human monoclonal antibody leads to
improved PET imaging with 89Zr-5B1. Mol pharm 2017;14:908-15.
27. Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of
orthotopic pancreatic cancer. Clin Cancer Res 2008;14:4951-60.
28. Kieler M, Unseld M, Bianconi D, Scheithauer W, Prager GW. A real-world analysis of second-line treatment options in pancreatic cancer:
liposomal-irinotecan plus 5-fluorouracil and folinic acid. Ther Adv Med Oncol 2019;11:1758835919853196.
29. Li X, Ma T, Zhang Q, Chen YG, Guo CX, et al. Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese
population. Cancer Lett 2017;406:22-6.
30. Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, et al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy
predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC cancer
2019;19:252.
31. Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, et al. CA19-9 decrease at 8 weeks as a predictor of overall survival in a
randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic
pancreatic cancer. Ann Oncol 2016;27:654-60.
32. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic
cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-6.
33. Satake K, Takeuchi T, Homma T, Ozaki H. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience.
Pancreas 1994;9:703-6.
34. Santucci N, Facy O, Ortega-Deballon P, Lequeu JB, Rat P, et al. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced
patients. Pancreatology 2018;18:666-70.
35. Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol
2015;21:3157.
36. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, et al. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in